Ryosuke Higuchi
Research Subjects
Ryosuke Higuchi has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
Itaru Takamisawa
34 shared publicationsTetsuya Tobaru
Department of Cardiology, Kawasaki Saiwai Hospital , 31-27 Omiya, Saiwai, Kawasaki, Kanagawa 212-0014
23 shared publicationsMorimasa Takayama
Hypertrophic Cardiomyopathy Center, Sakakibara Heart Institute, Tokyo, Japan
21 shared publicationsShuichiro Takanashi
21 shared publicationsMike Saji
Division of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine
18 shared publicationsMitsuaki Isobe
15 shared publications
Latest Publications
- Open Access
- 5 September 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (10) , 2348-2358
Temporal Trends and Outcomes in Low-Risk Patients Undergoing TAVI
- 5 September 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (10) , 2348-2358
Open AccessTemporal Trends and Outcomes in Low-Risk Patients Undergoing TAVI
- Open Access
- 27 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (9)
The jailed balloon technique for preventing coronary obstruction in the high-risk transcatheter aortic valve-in-transcatheter aortic valve
- 27 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (9)
Open AccessThe jailed balloon technique for preventing coronary obstruction in the high-risk transcatheter aortic valve-in-transcatheter aortic valve
- Open Access
- 27 August 2026
- Published by Elsevier in JACC: Asia
Optimization of Commissural Alignment Using an Anatomy-Tailored Method for a Supra-Annular Self-Expanding Transcatheter Heart Valve
- 27 August 2026
- Published by Elsevier in JACC: Asia
Open AccessOptimization of Commissural Alignment Using an Anatomy-Tailored Method for a Supra-Annular Self-Expanding Transcatheter Heart Valve
- Open Access
- 10 December 2025
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 7 (12) , 1304-1305
Incidence and Predictors of Valve Pop-up During Navitor Valve Implantation
Background: The Navitor valve shows excellent valve function and high deliverability. However, valve pop-up during valve implantation remains a concern.Methods and Results: We defined pop-up as an upward valve dislocation ≥3 mm after implantation. Pop-up occurred in 13 (19%) of 67 patients, with 2 (3.0%) patients requiring a second valve. The depth ratio between non- and left-coronary cusp side at the 80% release and aortic valve calcification score were identified as predictors of valve pop-up.Conclusions: Pop-up of the Navitor valve occurred in 19% of patients. Inconsistent valve depth and severe leaflet calcification were predictors of valve pop-up.
- 10 December 2025
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 7 (12) , 1304-1305
Open AccessIncidence and Predictors of Valve Pop-up During Navitor Valve Implantation
Background: The Navitor valve shows excellent valve function and high deliverability. However, valve pop-up during valve implantation remains a concern.Methods and Results: We defined pop-up as an upward valve dislocation ≥3 mm after implantation. Pop-up occurred in 13 (19%) of 67 patients, with 2 (3.0%) patients requiring a second valve. The depth ratio between non- and left-coronary cusp side at the 80% release and aortic valve calcification score were identified as predictors of valve pop-up.Conclusions: Pop-up of the Navitor valve occurred in 19% of patients. Inconsistent valve depth and severe leaflet calcification were predictors of valve pop-up.
Validation of the European Society of Cardiology 0/1-hour algorithm for chest pain triage in Asian emergency departments: a multinational stepped-wedge cluster-randomised trial
Background Rapid triage of patients presenting with chest pain is essential for early diagnosis and safe disposition. The European Society of Cardiology (ESC) 0/1-hour hs-cTn algorithm has shown promising performance in Western cohorts, but evidence supporting its implementation in diverse Asian emergency department (ED) settings remains limited. Therefore, we evaluated the safety and clinical utility of the ESC 0/1-hour algorithm for chest pain triage across multiple Asian EDs. Methods This was a prospective, stepped-wedge, cluster-randomised trial conducted across 12 hospitals in five Asian countries, enrolling 3869 patients with suspected acute coronary syndrome without ST elevation (NSTE-ACS). Usual care involved troponin testing without standardised timing, whereas the 0/1-hour protocol followed ESC recommendations using high-sensitivity cardiac troponin T testing at baseline and 1 hour. The primary endpoint was 30-day major adverse cardiac events (MACE), including cardiovascular death, myocardial infarction (MI) and unplanned revascularisation. Non-inferiority was assessed using a one-sided 95% CI with a margin of 1.5%. Results Of 3869 patients (2059 usual care; 1810 0/1-hour care), MACE occurred in 1.7% of usual care patients and 1.4% in the 0/1-hour care (upper one-sided 95% CI –0.3%), confirming non-inferiority. ED discharge rates were significantly higher with the 0/1-hour algorithm (60% vs 35%, pConclusion The ESC 0/1-hour algorithm is safe and effective for rapid triage of chest pain in Asian EDs. These findings provide external validation of the 0/1-hour algorithm and support broader global implementation. Trial registration number UMIN000042461.
Validation of the European Society of Cardiology 0/1-hour algorithm for chest pain triage in Asian emergency departments: a multinational stepped-wedge cluster-randomised trial
Background Rapid triage of patients presenting with chest pain is essential for early diagnosis and safe disposition. The European Society of Cardiology (ESC) 0/1-hour hs-cTn algorithm has shown promising performance in Western cohorts, but evidence supporting its implementation in diverse Asian emergency department (ED) settings remains limited. Therefore, we evaluated the safety and clinical utility of the ESC 0/1-hour algorithm for chest pain triage across multiple Asian EDs. Methods This was a prospective, stepped-wedge, cluster-randomised trial conducted across 12 hospitals in five Asian countries, enrolling 3869 patients with suspected acute coronary syndrome without ST elevation (NSTE-ACS). Usual care involved troponin testing without standardised timing, whereas the 0/1-hour protocol followed ESC recommendations using high-sensitivity cardiac troponin T testing at baseline and 1 hour. The primary endpoint was 30-day major adverse cardiac events (MACE), including cardiovascular death, myocardial infarction (MI) and unplanned revascularisation. Non-inferiority was assessed using a one-sided 95% CI with a margin of 1.5%. Results Of 3869 patients (2059 usual care; 1810 0/1-hour care), MACE occurred in 1.7% of usual care patients and 1.4% in the 0/1-hour care (upper one-sided 95% CI –0.3%), confirming non-inferiority. ED discharge rates were significantly higher with the 0/1-hour algorithm (60% vs 35%, pConclusion The ESC 0/1-hour algorithm is safe and effective for rapid triage of chest pain in Asian EDs. These findings provide external validation of the 0/1-hour algorithm and support broader global implementation. Trial registration number UMIN000042461.
- Open Access
- 8 November 2025
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 90 (9) , CJ-25-0500-1263
Outcomes of Hemodialysis Patients Undergoing Contemporary Transcatheter Aortic Valve Implantation ― Insights From the LAPLACE-TAVI Registry ―
Background: Transcatheter aortic valve implantation (TAVI) is an alternative to surgical aortic valve replacement in hemodialysis patients; however, contemporary outcomes and risk stratifications remain unreported.Methods and Results: Using data from a multicenter database, this study included 2,888 patients who underwent TAVI between 2021 and 2024: 336 (11.6%) on hemodialysis and 2,552 (88.4%) not. The primary outcome was all-cause death after TAVI; the median follow-up was 527 days. Hemodialysis patients were younger, predominantly male, and had more comorbidities with higher surgical risk. Hemodialysis and non-hemodialysis patients had similar 30-day mortality (2.9% vs. 1.5%, respectively) and major procedural complications. Hemodialysis patients had 2- to 3-fold higher rates of all-cause death (14.4% vs. 6.5% at 1-year; 21.5% vs. 11.0% at 2 years), cardiovascular death, and the composite of all-cause death and heart failure hospitalization. After adjusting for confounders, hemodialysis had no significant effect on all-cause death and the composite endpoint. Body mass index, Clinical Frailty Scale, and albumin levels were associated with all-cause death in hemodialysis patients, allowing risk stratification into low-, intermediate-, and high-risk groups.Conclusions: In this study, hemodialysis patients were younger and had more comorbidities, but 30-day mortality and complications were similar to the non-hemodialysis group. Although hemodialysis patients had higher all-cause mortality, the worse outcomes in this group were attributed to comorbidities rather than the hemodialysis itself.
- 8 November 2025
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 90 (9) , CJ-25-0500-1263
Open AccessOutcomes of Hemodialysis Patients Undergoing Contemporary Transcatheter Aortic Valve Implantation ― Insights From the LAPLACE-TAVI Registry ―
Background: Transcatheter aortic valve implantation (TAVI) is an alternative to surgical aortic valve replacement in hemodialysis patients; however, contemporary outcomes and risk stratifications remain unreported.Methods and Results: Using data from a multicenter database, this study included 2,888 patients who underwent TAVI between 2021 and 2024: 336 (11.6%) on hemodialysis and 2,552 (88.4%) not. The primary outcome was all-cause death after TAVI; the median follow-up was 527 days. Hemodialysis patients were younger, predominantly male, and had more comorbidities with higher surgical risk. Hemodialysis and non-hemodialysis patients had similar 30-day mortality (2.9% vs. 1.5%, respectively) and major procedural complications. Hemodialysis patients had 2- to 3-fold higher rates of all-cause death (14.4% vs. 6.5% at 1-year; 21.5% vs. 11.0% at 2 years), cardiovascular death, and the composite of all-cause death and heart failure hospitalization. After adjusting for confounders, hemodialysis had no significant effect on all-cause death and the composite endpoint. Body mass index, Clinical Frailty Scale, and albumin levels were associated with all-cause death in hemodialysis patients, allowing risk stratification into low-, intermediate-, and high-risk groups.Conclusions: In this study, hemodialysis patients were younger and had more comorbidities, but 30-day mortality and complications were similar to the non-hemodialysis group. Although hemodialysis patients had higher all-cause mortality, the worse outcomes in this group were attributed to comorbidities rather than the hemodialysis itself.
- Open Access
- 8 January 2025
- Published by BMJ in Open Heart
- Vol. 12 (1) , e003112
Clinically relevant haemolysis after transcatheter aortic valve implantation with new-generation balloon-expandable valve
Background: Valve-related haemolysis is a known complication following prosthetic valve surgery. Haemolysis after transcatheter aortic valve implantation (TAVI) has been reported in some studies, all of which were non-critical. Data related to haemolysis associated with new-generation balloon-expandable valve (BEV) are scarce. Methods: Among 441 patients who underwent TAVI between April 2023 and June 2024, 282 patients treated with new-generation BEV were analysed. Haemolysis was defined based on the lactate dehydrogenase, haemoglobin, reticulocyte and haptoglobin levels. Clinically relevant haemolysis was defined as a case requiring transfusion and/or reintervention. Results: Clinically relevant haemolysis occurred in 6 of 282 patients (2.1%), with median age of 84 years. Three (50%) received a 20 mm valve, and the oversizing ranged from −6.6% to +2.7%. All patients (100%) exhibited paravalvular leakage at the native commissural sites, with moderate or greater paravalvular leakage in two (33%). Lactate dehydrogenase levels exceeded 1200 IU/L in five (83%), four (67%) required transfusion and three (50%) underwent reintervention: balloon aortic valvuloplasty in one and valve-in-valve procedures in two. Haemolysis regressed in three reintervention cases; however, one patient died 9 days postoperatively due to COVID-19. Among three patients (50%) managed conservatively, one developed prosthetic valve endocarditis, whereas another showed spontaneous regression of haemolysis. Over a median follow-up of 218 days, five patients (83%) survived. Conclusion: Clinically relevant haemolysis occurred in 2.1% of patients undergoing TAVI with new-generation BEV, with 67% requiring transfusion and 50% undergoing reintervention. Further research is warranted to identify risk factors and optimise management strategies for haemolysis.
- 8 January 2025
- Published by BMJ in Open Heart
- Vol. 12 (1) , e003112
Open AccessClinically relevant haemolysis after transcatheter aortic valve implantation with new-generation balloon-expandable valve
Background: Valve-related haemolysis is a known complication following prosthetic valve surgery. Haemolysis after transcatheter aortic valve implantation (TAVI) has been reported in some studies, all of which were non-critical. Data related to haemolysis associated with new-generation balloon-expandable valve (BEV) are scarce. Methods: Among 441 patients who underwent TAVI between April 2023 and June 2024, 282 patients treated with new-generation BEV were analysed. Haemolysis was defined based on the lactate dehydrogenase, haemoglobin, reticulocyte and haptoglobin levels. Clinically relevant haemolysis was defined as a case requiring transfusion and/or reintervention. Results: Clinically relevant haemolysis occurred in 6 of 282 patients (2.1%), with median age of 84 years. Three (50%) received a 20 mm valve, and the oversizing ranged from −6.6% to +2.7%. All patients (100%) exhibited paravalvular leakage at the native commissural sites, with moderate or greater paravalvular leakage in two (33%). Lactate dehydrogenase levels exceeded 1200 IU/L in five (83%), four (67%) required transfusion and three (50%) underwent reintervention: balloon aortic valvuloplasty in one and valve-in-valve procedures in two. Haemolysis regressed in three reintervention cases; however, one patient died 9 days postoperatively due to COVID-19. Among three patients (50%) managed conservatively, one developed prosthetic valve endocarditis, whereas another showed spontaneous regression of haemolysis. Over a median follow-up of 218 days, five patients (83%) survived. Conclusion: Clinically relevant haemolysis occurred in 2.1% of patients undergoing TAVI with new-generation BEV, with 67% requiring transfusion and 50% undergoing reintervention. Further research is warranted to identify risk factors and optimise management strategies for haemolysis.
- Open Access
- 24 December 2024
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 5 (1) , oeaf008
The Triglycerides, total Cholesterol, and Body weight Index associating with frailty and predicting poor outcome after transcatheter aortic valve implantation: insights from LAPLACE-TAVI registry
Aims: The nutritional status and frailty are crucial in patients with aortic stenosis undergoing transcatheter aortic valve implantation (TAVI), as they significantly impact outcomes. We have previously developed an easily calculable nutritional index, TCBI (Triglycerides, total Cholesterol, and Body weight Index), which has been validated as a prognostic indicator in various cardiovascular disease contexts. This study aimed to evaluate the impact of a low TCBI on the frailty and outcomes of patients undergoing TAVI. Methods and results: This study is a part of a Japanese multi-centre prospective registry database of TAVI cases (n = 824). Participants were categorized into three groups based on TCBI tertiles before TAVI. The primary endpoint was all-cause mortality with a follow-up duration of up to 3 years. In the lowest TCBI tertile group, motor functions reflecting frailty were substantially impaired, and cumulative incidences of primary endpoint was significantly higher compared to other groups. Multivariate Cox proportional hazard analyses adjusted by risk factors for poor outcomes following TAVI identified low TCBI significantly associated with an increased risk of the primary endpoint [hazard ratio (HR) and 95% confidence interval (95% CI) of 1 SD lower TCBI for all-cause mortality: 1.52, 1.08–2.13, P = 0.015]. Moreover, in individuals who experienced serious preprocedural complications, the negative prognostic impact of low TCBI was significantly amplified (HR and 95% CI: 4.9, 1.9–12.5, P < 0.001). Conclusion: The present findings underscore the importance of nutritional assessment in patients undergoing TAVI. TCBI proved useful for accurate risk stratification and determining TAVI procedural strategies.
- 24 December 2024
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 5 (1) , oeaf008
Open AccessThe Triglycerides, total Cholesterol, and Body weight Index associating with frailty and predicting poor outcome after transcatheter aortic valve implantation: insights from LAPLACE-TAVI registry
Aims: The nutritional status and frailty are crucial in patients with aortic stenosis undergoing transcatheter aortic valve implantation (TAVI), as they significantly impact outcomes. We have previously developed an easily calculable nutritional index, TCBI (Triglycerides, total Cholesterol, and Body weight Index), which has been validated as a prognostic indicator in various cardiovascular disease contexts. This study aimed to evaluate the impact of a low TCBI on the frailty and outcomes of patients undergoing TAVI. Methods and results: This study is a part of a Japanese multi-centre prospective registry database of TAVI cases (n = 824). Participants were categorized into three groups based on TCBI tertiles before TAVI. The primary endpoint was all-cause mortality with a follow-up duration of up to 3 years. In the lowest TCBI tertile group, motor functions reflecting frailty were substantially impaired, and cumulative incidences of primary endpoint was significantly higher compared to other groups. Multivariate Cox proportional hazard analyses adjusted by risk factors for poor outcomes following TAVI identified low TCBI significantly associated with an increased risk of the primary endpoint [hazard ratio (HR) and 95% confidence interval (95% CI) of 1 SD lower TCBI for all-cause mortality: 1.52, 1.08–2.13, P = 0.015]. Moreover, in individuals who experienced serious preprocedural complications, the negative prognostic impact of low TCBI was significantly amplified (HR and 95% CI: 4.9, 1.9–12.5, P < 0.001). Conclusion: The present findings underscore the importance of nutritional assessment in patients undergoing TAVI. TCBI proved useful for accurate risk stratification and determining TAVI procedural strategies.
- Open Access
- 8 November 2024
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 6 (11) , 505-513
Outcomes of Older Patients With Cardiogenic Shock Using the Impella Device ― Insights From the Japanese Registry for Percutaneous Ventricular Assist Device (J-PVAD) ―
Background: Aging has progressed in several regions of the world with more older patients experiencing acute cardiovascular disease. Impella is a percutaneous potent circulatory support device associated with substantial cost and potential device-related complications.Methods and Results: We analyzed the Japanese nationwide registry, encompassing consecutive patients with cardiogenic shock using Impella. Among 5,718 patients treated between 2020 and 2022, we compared older patients (≥75 years) with younger patients. The primary outcome was the Kaplan-Meier estimated 30-day mortality, and the secondary outcome was Impella-related complications. The median age of the 5,718 patients was 69 (58–77) years, and 1,807 (31.6%) were older, with smaller body mass index, frequent acute coronary syndrome, and infrequent myocarditis. Comorbidities were frequently observed in older patients with a higher ejection fraction and less frequency of extracorporeal membrane oxygenation. Older patients had a higher 30-day mortality than younger patients (38.9% vs. 32.5%; P<0.0001). The 30-day mortality was statistically equivalent among older subsets (75–79 vs. 80–84 vs. ≥85 years). Device-related complications similarly occurred similarly among the older subsets, except for a modest increase in cardiac tamponade and limb ischemia. Older age, body mass index, myocarditis, prior arrhythmia, shock severity, renal and hepatic impairment, and limb ischemia were associated with 30-day mortality.Conclusions: The selected older patients using Impella exhibited modestly higher 30-day mortality with similar safety profiles. A longer follow up and optimal patient selection are important.
- 8 November 2024
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 6 (11) , 505-513
Open AccessOutcomes of Older Patients With Cardiogenic Shock Using the Impella Device ― Insights From the Japanese Registry for Percutaneous Ventricular Assist Device (J-PVAD) ―
Background: Aging has progressed in several regions of the world with more older patients experiencing acute cardiovascular disease. Impella is a percutaneous potent circulatory support device associated with substantial cost and potential device-related complications.Methods and Results: We analyzed the Japanese nationwide registry, encompassing consecutive patients with cardiogenic shock using Impella. Among 5,718 patients treated between 2020 and 2022, we compared older patients (≥75 years) with younger patients. The primary outcome was the Kaplan-Meier estimated 30-day mortality, and the secondary outcome was Impella-related complications. The median age of the 5,718 patients was 69 (58–77) years, and 1,807 (31.6%) were older, with smaller body mass index, frequent acute coronary syndrome, and infrequent myocarditis. Comorbidities were frequently observed in older patients with a higher ejection fraction and less frequency of extracorporeal membrane oxygenation. Older patients had a higher 30-day mortality than younger patients (38.9% vs. 32.5%; P<0.0001). The 30-day mortality was statistically equivalent among older subsets (75–79 vs. 80–84 vs. ≥85 years). Device-related complications similarly occurred similarly among the older subsets, except for a modest increase in cardiac tamponade and limb ischemia. Older age, body mass index, myocarditis, prior arrhythmia, shock severity, renal and hepatic impairment, and limb ischemia were associated with 30-day mortality.Conclusions: The selected older patients using Impella exhibited modestly higher 30-day mortality with similar safety profiles. A longer follow up and optimal patient selection are important.
- Open Access
- 23 September 2024
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (1) , 408-417
Prognostic Impact of Being Underweight in Patients Undergoing Mitral TEER: The OCEAN-Mitral Registry
Aims: Mitral transcatheter edge-to-edge repair (M-TEER) is a valid treatment option for severe mitral regurgitation (MR), necessitating accurate risk stratification of M-TEER candidates for effective patient selection, optimal periprocedural care and improved long-term outcomes. The body mass index (BMI) is a simple and practical prognostic index, and the obesity paradox has been widely reported. Methods and Results: Between April 2018 and June 2021, 2149 patients undergoing M-TEER were registered in the prospective multicentre registry and classified into three groups: underweight (BMI < 18.5 kg/m2), normal weight (18.5 ≤ BMI < 25 kg/m2) and overweight and obese (25 kg/m2 ≦ BMI) [Correction added on 17 October 2024, after first online publication: In the preceding sentence, “18.5 ☆ BMI < 25 kg/m2” and “25 kg/m2 ☆ BMI” have been corrected to “18.5 ≤ BMI < 25 kg/m2” and “25 kg/m2 ≦ BMI” in this version.] The impact of underweight on the all-cause, cardiovascular and non-cardiovascular mortality following M-TEER was evaluated [follow-up duration: 436 (363–733) days]. The participants (median BMI: 21.1 kg/m2) were categorized as underweight (n = 450, 20.9%), normal weight (n = 1409, 65.6%) and overweight and obese (n = 290, 13.5%). Compared with the other two groups, the underweight group exhibited several negative prognostic factors, including older age, frailty, no dyslipidaemia, hypoalbuminaemia, residual MR and non-home discharge. Underweight patients had the highest rate of all-cause, cardiovascular and non-cardiovascular mortality, whereas those in the other two groups were similar. As per the multivariate analysis, underweight itself was associated with all-cause mortality (hazard ratio: 1.52, 95% confidence interval: 1.17–1.97, P = 0.009) and cardiovascular mortality (hazard ratio: 1.45, 95% confidence interval: 1.04–2.01, P = 0.028). Conclusions: Underweight patients had the highest mortality rate after M-TEER. Comorbidities, residual MR, discharge disposition and underweight status were correlated with postprocedural outcome.
- 23 September 2024
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (1) , 408-417
Open AccessPrognostic Impact of Being Underweight in Patients Undergoing Mitral TEER: The OCEAN-Mitral Registry
Aims: Mitral transcatheter edge-to-edge repair (M-TEER) is a valid treatment option for severe mitral regurgitation (MR), necessitating accurate risk stratification of M-TEER candidates for effective patient selection, optimal periprocedural care and improved long-term outcomes. The body mass index (BMI) is a simple and practical prognostic index, and the obesity paradox has been widely reported. Methods and Results: Between April 2018 and June 2021, 2149 patients undergoing M-TEER were registered in the prospective multicentre registry and classified into three groups: underweight (BMI < 18.5 kg/m2), normal weight (18.5 ≤ BMI < 25 kg/m2) and overweight and obese (25 kg/m2 ≦ BMI) [Correction added on 17 October 2024, after first online publication: In the preceding sentence, “18.5 ☆ BMI < 25 kg/m2” and “25 kg/m2 ☆ BMI” have been corrected to “18.5 ≤ BMI < 25 kg/m2” and “25 kg/m2 ≦ BMI” in this version.] The impact of underweight on the all-cause, cardiovascular and non-cardiovascular mortality following M-TEER was evaluated [follow-up duration: 436 (363–733) days]. The participants (median BMI: 21.1 kg/m2) were categorized as underweight (n = 450, 20.9%), normal weight (n = 1409, 65.6%) and overweight and obese (n = 290, 13.5%). Compared with the other two groups, the underweight group exhibited several negative prognostic factors, including older age, frailty, no dyslipidaemia, hypoalbuminaemia, residual MR and non-home discharge. Underweight patients had the highest rate of all-cause, cardiovascular and non-cardiovascular mortality, whereas those in the other two groups were similar. As per the multivariate analysis, underweight itself was associated with all-cause mortality (hazard ratio: 1.52, 95% confidence interval: 1.17–1.97, P = 0.009) and cardiovascular mortality (hazard ratio: 1.45, 95% confidence interval: 1.04–2.01, P = 0.028). Conclusions: Underweight patients had the highest mortality rate after M-TEER. Comorbidities, residual MR, discharge disposition and underweight status were correlated with postprocedural outcome.